Pharmacotherapy of Obsessive-Compulsive Disorder

  • Jambur Ananth


Obsessive-compulsive disorder (OCD) has attracted the attention of many investigators from time immemorial because of the rarity of the disease, the distinctive clinical picture, and the ego-alien nature of the symptoms. Over time, many methods of treatment have been tried, unfortunately, with little success. Thus, pessimism has been generally expressed by many workers regarding the outcome of therapeutic intervention (Kolb, 1968; Lewis, A., 1935; Pollitt, 1957). However, with the progress achieved over the past 20 years in the psychological and somatic treatments of this disorder, there is reason for optimism. Hopefully, the new directions will also provide new insights in the understanding of this crippling disorder. Basic to treatment and evaluation of efficacy are the problems of diagnosis, assessment, and the rationale for treatment.


Canadian Medical Association Journal Obsessive Symptom Neurotic Patient Depressive Psychosis Obsessional Neurosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akimoto, H., Nakakuki, M., & Machiyama, Y. Clinical experiences with MAO inhibitors (a comparison with Tofranil). Diseases of the Nervous System, 1960, 21, 645–647.PubMedGoogle Scholar
  2. Altschuler, M. Massive doses of trifluoperazine in the treatment of compulsive rituals. American Journal of Psychiatry, 1962, 119, 367–368.PubMedGoogle Scholar
  3. Alzheimer, O. Zur Pharmacotherapie depressiver erkrankungen. Medizinische Welt, 1960, 37, 1918–1926.PubMedGoogle Scholar
  4. Amat Aguirre, E. Tratamiento de las depresiones atfpicas. Revue Informacion Medicale-Thera pie, 1966, 41, 387–392.Google Scholar
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders ( 3rd ed. ). Washington, DC: Author, 1980.Google Scholar
  6. Amin, M. M., Ban, T. A., Pecknold, J. C., & Klingner, A. Clomipramine (Anafranil) and behavior therapy in obsessive-compulsive and phobic disorders. Journal of International Medical Research, 1977, 5, (Suppl. 5), 33–37.PubMedGoogle Scholar
  7. Ananth, J. Pathophysiology of tardive dyskinesia. Neu ropsychobiology, 1982, 8, 210–212.Google Scholar
  8. Van Den Steen, N. Systematic studies in the treatment of obsessive-compulsive neurosis with tricyclic antidepressants. Current Therapeutic Research, 1977, 21, 495–501.Google Scholar
  9. Ananth, J., Solyom, L., Solyom, C., & Sookman, D. Doxepin in the treatment of obsessive compulsive neurosis. Psychosomatics, 1975, 16, 185–187.PubMedGoogle Scholar
  10. Ananth, J., Solyom, L., Bryntwick, S., & Krishnappa, U. Clomipramine therapy for obsessive compulsive neurosis. American Journal of Psychiatry, 1979, 135, 700–701.Google Scholar
  11. Ananth, J., Pecknold, J., Van Den Steen, N., & Engelsmann, F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuro-Psychopharmacology, 1981, 5, 257–262.PubMedGoogle Scholar
  12. Anden, N. G. Oral L-dopa treatment of Parkinsonism. Acta Medica Scandinavica, 1970, 187, 247–255.PubMedGoogle Scholar
  13. Annesley, P. T. Nardil response in a chronic obsessive compulsive. British Journal of Psychiatry, 1969, 115, 748.PubMedGoogle Scholar
  14. Baker, E. F. W., Young, M. P., & Gould, D. M. A new look at bimedial prefrontal leukotomy. Canadian Medical Association Journal, 1970, 102, 37–41.PubMedGoogle Scholar
  15. Barbeau, A. Long-term side effects of levodopa. Lancet, 1971, 1, 395.PubMedGoogle Scholar
  16. Bauer, G., & Novak, H. Doxepine ein neuves Antidepressivum; Wirkungvergleich mit Amitriptylin. Arzneimittel-Forschung, 1969, 19, 1642–1646PubMedGoogle Scholar
  17. Bernstein, I., Callahan, W. A., & Jaranson, J. M. Lobotomy in private practice. Archives of General Psychiatry, 1975, 32, 1041–1047.Google Scholar
  18. Bethume, H. C. A new compound in the treatment of anxiety states: Report on the use of diazepam. New Zealand Medical Journal, 1964, 63, 153–156.Google Scholar
  19. Black, A. The natural history of obsessional neurosis. In H. H. Beech, H. H. (Ed.), Obsessive states. London: Methuen, 1974.Google Scholar
  20. Bonis, A., Covello, L., & Lemperiere, T. Etude critique des indications d’ interventions psychochirurgicales. Encephale, 1968, 57, 439–473, 525–563.Google Scholar
  21. Boucquey, J., & Boucquey, J. P. Traitement ambulatoire à l’imipramine de 50 cas de psychoneurosis. Revue Médicale de Louvain, 1961, 5, 126–142.Google Scholar
  22. Brickner, R. M., Rosen, A. A., & Munro, R. Physiological aspects of the obsessive state. Psychosomatic Medicine, 1940, 2, 369–383.Google Scholar
  23. Bridges, P. K., Goktepe, E. O., Maratos, J., Browne, A., & Young, L. A comparative review of patients with obsessional neurosis and with depression treated by psychosurgery. British Journal of Psychiatry, 1973, 123, 663–674.PubMedGoogle Scholar
  24. Brietner, C. Drug therapy in obsessional states and other psychiatric problems. Diseases of the Nervous System (Suppl.) 1960, 21, 31–35.Google Scholar
  25. Brown, F. W. Heredity in psychoneuroses. Proceedings of the Royal Society of Medicine, 1942, 35, 785–790.PubMedGoogle Scholar
  26. Burckhardt, G. Uber Rindenexcisionen, als Beitrag zur operativen Therapie der Psychosen. Allgemeine Zeitschrift Peur Psychiatrie, 1890, 74, 463.Google Scholar
  27. Burrell, R. H., Culpan, R. H., Newton, K. J. Use of bromazepam in obsessional, phobic and related states. Current Medical Research Opinion, 1974, 2, 430–436.Google Scholar
  28. Campbell, B., Gomez, L., Ananth, J. V., Bronheim, L. A., Klingner, A., & Ban, T. A. An uncontrolled clinical trial with clomipramine in the treatment of depressed patients. Current Therapeutic Research, 1973, 15, 223–231.PubMedGoogle Scholar
  29. Cartes Egea, F. Observaciones sobre el tratamiento ambulatorio de los estados depresivos con G 22355 (Tofranil). Medicina Clinica (Barcelona), 1961, 36, 448–452.Google Scholar
  30. Carman, J. S. Hyperdopaminergic states: A continuum. Lancet, 1972, 2, 1249.PubMedGoogle Scholar
  31. Cassano, G. G., Castrogiovanni, P., & Mauri, M. A multicenter controlled trial in phobic-obsessive psychoneurosis. The effect of chlorimipramine and its combinations with haloperidol and diazepam. Progress in Neuropsychopharmacology, 1981, 5, 129–138.Google Scholar
  32. Chapel, J. L. Gilles de la Tourette’s disease—The past and the present. Canadian Psychiatric Association Journal, 1966, 11, 324–329.PubMedGoogle Scholar
  33. Cooper, J. E. The Leyton Obsessive Inventory. Psychological Medicine, 1970, 1, 48–64.PubMedGoogle Scholar
  34. Lopez-Ibor Alino, J. J. La monochlorimiprame en enfornes psychiatrices resistantes en otros tratamientos. Acta Luso Espanol Neurologi Psychiatri, 1967, 26, 119–147.Google Scholar
  35. Crawford, J. F. Cerebral autonomic imbalance. Lancet, 1973, 2, 772–773.Google Scholar
  36. Creese, I., Bivet, D. R., & Snyder, S. H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science, 1977, 197, 596–598.PubMedGoogle Scholar
  37. Cruz, M. de la, & Sarro-Martin, A. Experiencias con un nuevo antidepressivo derivado del iminodibencilo. Medicina Clinica (Barcelona), 1959, 33, 122–125.Google Scholar
  38. Daily, P. Chemotherapy of psychiatric disorders. London: Logos Press, 1967.Google Scholar
  39. Dubois, J. C., & Rancurel, G. Vol et melancolie: A propos de cinq observations. Annales Médico-Psychologiques (Paris), 1967, 125, 572–579.Google Scholar
  40. Earle, B. V., & Earle, A. M. Imipramine (Tofranil) in mental health clinic and private practice. Canadian Medical Association Journal, 1960, 83, 804–806.PubMedGoogle Scholar
  41. Ellinwood, E. H., Jr. Amphetamine psychosis. I. Description of the individuals and the process. Journal of Nervous and Mental Disease, 1967, 144, 273–283.Google Scholar
  42. Ellinwood, E. H., Jr., & Escalante, O. Chronic amphetamine effect on the olfactory forebrain. Biological Psychiatry, 1970, 2, 189–203.PubMedGoogle Scholar
  43. Escobar, J., Teeter, R. R., Tuason, V. B., & Schiele, B. C. Intravenous chlorimipramine and depressive subtypes. Diseases of the Nervous System, 1976, 37, 325–328.PubMedGoogle Scholar
  44. Eysenck, H. The manual of Maudsley Personality Inventory. London: University of London Press, 1959.Google Scholar
  45. Freed, A., Kerr, T. A., & Roth, M. The treatment of obsessional neurosis. British Journal of Psychiatry, 1972, 120, 590–591.Google Scholar
  46. Freeman, W., & Watts, J. W. Psychosurgery: An evaluation of 200 cases over seven years. Journal of Mental Science, 1944, 90, 379–532.Google Scholar
  47. Frossman, H., & Walinder, J. Lithium treatment on atypical indication. Acta Psychiatrica Scandinavica, 1969 (Suppl. 207 ), 34–40.Google Scholar
  48. Garmany, G., May, A. R., & Folkson, A. The use and action of chlorpromazine in psychoneuroses. British Medical Journal, 1954, 3, 439–441.Google Scholar
  49. Gattuso, S., & Coaciuri, V. L’imipramine nella terapia della nevrosi assessiva. Acta Neurologica (Napoli) 1964, 19, 424–431.Google Scholar
  50. Geister, A., & Schou, M. Lithium for obsessive neurosis. Nordisk Psykiatrisk Tidsskrift, 1969, 23, 493–495.Google Scholar
  51. Geissmann, P., & Kammerer, T. L’imipramine dans la nevrose obsessionnelle. Etude de 30 cas. Encephale, 1964, 53, 369–382.Google Scholar
  52. Gittelson, N. L. The effect of obsessions in depressive psychosis. British of Psychiatry, 1966, 112, 253–259.Google Scholar
  53. Gittelson, N. L. The phenomenology of obsessions in depressive psychosis. British Journal of Psychiatry, 1996, 112, 261–264.Google Scholar
  54. Gittelson, N. L. The fate obsessions in depressive psychosis. British Journal of Psychiatry, 1966, 112, 705–708.Google Scholar
  55. Gittelson, N. L. Depressive psychosis in obsessional neurotics. British Journal of Psychiatry, 1966, 112, 883–887.Google Scholar
  56. Goodwin, D. W., Guze, S. B., & Robins, E. Follow up studies in obsessional neurosis. Archives of General Psychiatry, 1969, 20, 182–187.PubMedGoogle Scholar
  57. Grimshaw, L. The outcome of obsessional disorder: A follow up study of 100 cases. British Journal of Psychiatry, 1965, 111, 1051–1056.PubMedGoogle Scholar
  58. Guyotat, J., Marin, A., Dubor, P., & Bonhomme, R. L’imipramine en dehors des états dépressifs. Journal Médicale Lyon, 1960, 41, 367–375.Google Scholar
  59. Hohne, H. H., & Walsh, K. W. Surgical modification of personality: Mental health research project. Melbourne, Australia: Victorian Mental Health Authority, 1970.Google Scholar
  60. Holden, J. M. C., Itil, T. M., & Hofstatter, L. Prefrontal lobotomy: Stepping stone or pitfall ? American Journal of Psychiatry, 1970, 127, 591–598.PubMedGoogle Scholar
  61. Hussain, M. Z., & Ahad, A. Treatment of obsessive compulsive neurosis. Canadian Medical Association Journal, 1970, 103, 648–650.Google Scholar
  62. Insel, T. R., & Murphy, D. L. The pharmacological treatment of obsessive-compulsive disorder: A review. Journal of Clinical Psychopharmacology, 1981, 1, 304–311.Google Scholar
  63. Isberg, R. S. A comparison of phenelzine and imipramine in an obsessivecompulsive patient. American Journal of Psychiatry, 1981, 138, 1250–1251.PubMedGoogle Scholar
  64. Jain, V. K., Swinson, R. P., & Thomas, J. G. Phenelzine in obsessional neurosis. British Journal of Psychiatry, 1970, 117, 237–238.PubMedGoogle Scholar
  65. Janowski, D. S., Davis, J. M., El Yousef, M. K., & Sekerke, H. J. A cholinergicadrenergic hypothesis of mania and depression. Lancet, 1972, 2, 632–635.Google Scholar
  66. Jenike, M. A. Rapid response of severe obsessive compulsive disorder to tranylcypromine. American Journal of Psychiatry, 1981, 138, 1249–1251.PubMedGoogle Scholar
  67. Jimenz Garcia, P. Experiencia clinica con clomipramina en enfermos psychiâtricos. Libro de Becas Cursos, 1967, 58, 179–201.Google Scholar
  68. Kalinowsky, L. B., & Hippius, H. Pharmacological, convulsive, and other somatic treatments in psychiatry. New York: Grune & Stratton, 1969.Google Scholar
  69. Kalinowsky, L. G., & Hoch, P. H. Somatic treatments in psychiatry. New York: Grune & Stratton, 1961.Google Scholar
  70. Kanner, L. Clinical psychiatry ( 3rd ed. ). Springfield, IL: Charles C Thomas, 1957.Google Scholar
  71. Karabanow, O. Double-blind controlled study in phobias and obsessions complicated by depression. International Journal of Medical Research, 1977, 5, (Suppl. 5), 42–48.Google Scholar
  72. Kelly, D., Walter, C. J. S., & Mitchell-Heggs, N. Modified leucotomy assessed clinically, physiologically and psychologically at six weeks and eighteen months. British Journal of Psychiatry, 1972, 120, 19–29.PubMedGoogle Scholar
  73. Kelly, D. Therapeutic outcome in limbic leucotomy in psychiatric patients. Psychiatry, Neurology, Neurosurgery (Amsterdam), 1976, 76, 353–363.Google Scholar
  74. Kendell, R. E., & Discipio, W. J. Obsessive symptoms and obsessional personality traits in patients with depressive illnesses. Psychological Medicine, 1970, 1, 65–72.PubMedGoogle Scholar
  75. Klawan, H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry, 1973, 130, 82–86.Google Scholar
  76. Knight, G. Bifrontal stereotractotomy. British Journal of Psychiatry, 1969, 115, 257–266.PubMedGoogle Scholar
  77. Kolb, L. C. Noyse’s modern clinical psychiatry. Philadelphia: W. B. Saunders, 1968.Google Scholar
  78. Kramer, M. Delirium as a complication of imipramine therapy in the aged. American Journal of Psychiatry, 1963, 120, 502–503.PubMedGoogle Scholar
  79. Kringlen, E. Natural history of obsessional neurosis. Seminars in Psychiatry, 1970, 2, 403–419.PubMedGoogle Scholar
  80. Laboucarie, J., Rascol, A., Jorda, P., Guraud, R., & Leinadier, H. New prospects in the treatment of melancholic states. Therapeutic study of a major antidepressant, chlorimipramine. Revue Médicale de Toulouse, 1967, 3, 863–872.Google Scholar
  81. Lewin, W. Selective leucotomy: A review. In L. Laininen & K. E. Livingston (Eds.), Surgical approaches in psychiatry. England: Medical and Technical Publishing Co., Ltd., 1973.Google Scholar
  82. Lewis, A. Problems of obsessional illness. Proceedings of the Royal Society of Medicine, 1935, 29, 325–336.Google Scholar
  83. Linford-Rees, W. The value and limitations of psychosurgery in the treatment of psychiatric illness. Psychiatry, Neurology, Neurosurgery (Amsterdam), 1973, 76, 323–334.Google Scholar
  84. Lo, W. H. A follow-up study of obsessional neurotics in Hong Kong Chinese. British Journal of Psychiatry, 1997, 113, 823–832.Google Scholar
  85. Lopez-Ibor, Alino, J. J. Intravenous perfusion of monochlorimipramine. Techniques and results. In Proceedings of the International College of CINP, Teragone, April, 1968 (International Congress Series, 180, 519 ). Netherlands. Excerpta Medica, 1969.Google Scholar
  86. Marks, I. M., Birley, J. L. T., & Gelder, M. G. Modified leucotomy in severe agoraphobia: A controlled serial enquiry. British Journal of Psychiatry, 1966, 112, 757–769.PubMedGoogle Scholar
  87. Marks, I. M., Stern, R. S., Mawson, D., Cobb, J., & McDonald, R. Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 1980, 136, 1–25.PubMedGoogle Scholar
  88. Marshall, W. K. Treatment of obsessional illness and phobic anxiety state with clomipramine. British Journal of Psychiatry, 1971, 119, 467–468.PubMedGoogle Scholar
  89. Marshall, W. K. & Micev, V. Clomipramine in the treatment of obsessional illness and phobic anxiety states. Journal of International Medical Research, 1973, 1, 403–412.Google Scholar
  90. Matigama, Y., Kuroiwa, S., & Naruse, H. Some clinical experience with a new iminodibenzyl derivative G.22344 (Tofranil) (Japan). Bulletin of the SeishinIgaku Institute [Clinical Psychiatry], 1959, 1, 581–585.Google Scholar
  91. Meyer, G., McElhaney, M., Martin, W., & McGraw, C. P. Stereotactic cingulotomy with results of acute stimulation and serial psychological testing. In L. Laininen & K. E. Livingston (Eds.), Surgical Approaches in Psychiatry. Baltimore: Baltimore University Press, 1973.Google Scholar
  92. Meyer-Gross, W., Slater, E., & Roth, M. Clinical Psychiatry. London: Bailliere, Tindal & Cassell, 1969.Google Scholar
  93. Michaux, L., Duche, D., & Perpinoitis. Etude pharmocodynamique, clinique et therapeutique du G22344 en pedo-psychiatrie. Proceedings of the 3rd World Congress of Psychiatry, Montreal, 1961, 2, 927–929 (McGill, Montreal, 1961 ).Google Scholar
  94. Miller, H. Psychosurgery & Dr. Breggin. New Scientist, 1972, 55, 188–190.Google Scholar
  95. Moniz, E. Tentative opératoires dans le traitement de certaine psychoses. Paris: Masson, 1936.Google Scholar
  96. Naviau, J., Ruyffelaere, J., & Lehembre, C. A propos de deux cas de nevrose obsessionnelle. Annales Médico-Psychologiques (Paris) 1966, 124, 254–258.Google Scholar
  97. Nauta, W. J. H. Some efferent connections of the prefrontal cortex in the monkey. In J. W. Warren & K. Akert (Eds.), Frontal granular cortex and behavior. New York: McGraw-Hill, 1964.Google Scholar
  98. O’Reagan, J. B. Treatment of obsessive compulsive neurosis with haloperidol. Canadian Medical Association Journal, 1970, 103, 167–168.Google Scholar
  99. Orvin, G. H. The treatment of the phobic obsessive compulsive patient with oxazepam, an improved benzodiazepine compound. Psychosomatics, 1967, 8, 278–280.PubMedGoogle Scholar
  100. Owen, F., Crow, T. J., Foulter, M., Cross, A. J., Longden, A., & Riley, G. J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet, 1978, 2, 223–226.PubMedGoogle Scholar
  101. Philpott, R. Recent advances in the behavioral measurement of obsessional difficulties common to these and other measures. Scottish Medical Journal, 1975, 20, 33–40.PubMedGoogle Scholar
  102. Pippard, J. Rostral leucotomy: A report on 240 cases personally followed up after 11/2 to 5 years. Journal of Mental Science, 1955, 101, 756–773.PubMedGoogle Scholar
  103. Pollitt, J. Natural history of obsessional states. British Medical Journal, 1957, 1, 194–198.PubMedGoogle Scholar
  104. Post, F., Rees, W. L., & Schurr, P. H. An evaluation of bimedial leucotomy. British Journal of Psychiatry, 1968, 114, 1223–1246.PubMedGoogle Scholar
  105. Prange, A. J., Sisk, J. L., Wilson, I. C., Morris, C. E., Hall, C. D., Carman, J. S. Proceedings of N.I.M.H. Serotonin Conference, Palo Alto, California. Washington: U.S. Government Printing Office, 1972.Google Scholar
  106. Rabavilas, A. D., Boulougouris, J. C., Perissaki, C., & Stefanis, C. The effect of peripheral beta-blockade on psychophysiologic responses in obsessional neurotics. Comprehensive Psychiatry, 1979, 20, 378–383.PubMedGoogle Scholar
  107. Rachman, S., Cobb, J., Grey, S., McDonald, B., Mawson, D., Sartory, G., & Stern, R. The behavioral treatment of obsessional-compulsive disorders with or without clomipramine. Behavioral Research & Therapy, 1979, 17, 467–478.Google Scholar
  108. Rachman, S. J., & Hodgson, R. J. Obsessions and compulsions. Englewood Cliffs, NJ: Prentice-Hall, 1980.Google Scholar
  109. Rao, A. V. A controlled trial with “valium” in obsessive compulsive state. Journal of the Indian Medical Association, 1964, 42, 564–567.Google Scholar
  110. Rapoport, J., Elkins, R., & Müelsen, E. A clinical controlled trial of chlorimipramine in adolescents with obsessive compulsive disorder. Psychopharmacology Bulletin, 1980, 16, 61–63.PubMedGoogle Scholar
  111. Renynghe de Voxrie, G. V. L’Anafranil dans l’obsession. Acta Neurologica Belgica, 1968, 68, 787–792.Google Scholar
  112. Robins, A. H. Depression in patients with Parkinsonism. British Journal of Psychiatry, 1976, 128, 141–145.PubMedGoogle Scholar
  113. Rosenberg, C. M. Complications of obsessional neurosis. British Journal of Psychiatry, 1968, 114, 477–478.PubMedGoogle Scholar
  114. Rylander, G. Clinical and medico criminological aspects of addictions to central stimulating drugs. In E. Sjoquist & E. Tottie (Eds.) Abuse of central stimulants. New York: Raven Press, 1969.Google Scholar
  115. Sakai, T. Clinicogenetic study on obsessive compulsive neurosis. Bulletin of Osaka Medical School, 1968, (Suppl. 12 ), 323–331.Google Scholar
  116. Sargant, W. & Slater, E. Discussion on the treatment of obsessional neuroses. Proceedings of the Royal Society of Medicine, 1950, 43, 1007–1010.Google Scholar
  117. Sargent, W. The present indications for leucotomy. Lancet, 1992, 1, 1197–1200.Google Scholar
  118. Schilder, P. The organic background of obsessions and compulsions. American Journal of Psychiatry, 1938, 94, 1397–1416.Google Scholar
  119. Schildkrout, J. J., & Kety, S. S. Biogenic amines and emotion. Science, 1967, 156, 21–30.Google Scholar
  120. Scoville, W. B. Late results of orbital undercutting. Report of 76 patients undergoing quantitative selective lobotomies. American Journal of Psychiatry, 1960, 117, 525–532.Google Scholar
  121. Shader, R. I. Antianxiety agents: A clinical perspective. In A. DiMascio & R. Shader (Eds.), Clinical handbook of psychopharmacology. New York: Science Press, 1970. 71–77.Google Scholar
  122. Shapiro, A. K., Shapiro, G., & Wayne, H. Treatment of Tourette’s syndrome. Archives of General Psychiatry, 1973, 28, 92–97.Google Scholar
  123. Shobe, F. O., & Gildea, M. C. L. Long-term follow-up of selected lobotomized private patients. Journal of American Medical Association, 1968, 206, 327–332.Google Scholar
  124. Singer, K. Gilles de la Tourette’s disease. American Journal of Psychiatry, 1963, 20, 80–81.Google Scholar
  125. Slater, E., & Roth, M. Clinical psychiatry (3rd ed.). Baltimore, MD: William & Wilkins, 1969.Google Scholar
  126. Snyder, S. Amitriptyline treatment of obsessive compulsive neurosis. Journal of Clinical Psychiatry, 1980, 41, 286–289.PubMedGoogle Scholar
  127. Solyom, L., & Sookman, D. A comparison of clomipramine hydrochloride (Anafranil) and behavioral therapy in the treatment of obsessive neurosis. Journal of International Medical Research, 1977, 5 (Suppl. 5), 49–61.PubMedGoogle Scholar
  128. Stern, T. A., & Jenike, M. A. Treatment of obsessive compulsive disorder with lithium carbonate. Psychosomatics, 1983, 24, 671–673.PubMedGoogle Scholar
  129. Strauss, H. Office treatment of depressive states with a new drug (imipramine). New York State Journal of Medicine, 1959, 59, 2906–2910.PubMedGoogle Scholar
  130. Strom-Olsen, R., & Carlisle, S. Bifrontal stereotractotomy: A follow up study of its effects on 210 patients. British Journal of Psychiatry, 1971, 118, 141–154.PubMedGoogle Scholar
  131. Sykes, M. K., & Tredgold, R. F. Restricted orbital undercutting: A study of its effects on 350 patients over the ten years, 1951–1960. British Journal of Psychiatry, 1964, 110, 609–640.PubMedGoogle Scholar
  132. Tan, E., Marks, I. M., & Marset, P. Bimedial leucotomy in obsessive compulsive neurosis: A controlled serial enquiry. British Journal of Psychiatry, 1971, 118, 155–164.PubMedGoogle Scholar
  133. Taylor, K. M., & Snyder, S. H. Amphetamine differentiation of D- and L-isomers of animal behavior involving central norepinephrine or dopamine. Science, 1970, 168, 1487–1489.PubMedGoogle Scholar
  134. Templer, D. I. The obsessional neurosis: A review of research findings. Comprehensive Psychiatry, 1972, 13, 375–383.PubMedGoogle Scholar
  135. Thoren, P., Asberg, M., Cronholm, B., Jorenstedt, L., & Traskman, L. Clomipramine treatment of obsessive-compulsive disorder: A controlled clinical trial. Archives of General Psychiatry, 1980, 37, 1281–1289.PubMedGoogle Scholar
  136. Tooth, G. C., & Newton, M. P. Leucotomy in England and Wales. London: Her Majesty’s Stationery Office, 1961.Google Scholar
  137. Trethowan, W. F., & Scott, P. A. L. Chlorpromazine in obsessive-compulsive neurosis and allied disorders. Lancet, 1955, 1, 781–785.Google Scholar
  138. Tucker, W. I. Indications for modified leucotomy. Lahey Clinic Foundation Bulletin, 1966, 15, 131–139.PubMedGoogle Scholar
  139. Turner, S. M., Hersen, M., Bellack, A. S., Andrasik, F., & Capparell, H. V. Behavioral and pharmacological treatment of obsessive-compulsive disorders. Journal of Nervous and Mental Disease, 1980, 168, 651–657.PubMedGoogle Scholar
  140. Vanggard, T. The concept of neurosis. Acta Psychiatrica Scandinavica, 1959, 16, 117–136.Google Scholar
  141. Van Hoesen, G. W., Pandya, D. N., & Butters, N. Cortical afferents to the entorhinal cortex of the rhesus monkey. Science, 1972, 175, 1471–1473.PubMedGoogle Scholar
  142. Van Putten, T., Sr Sanders, D. G. Lithium in treatment failures. Journal of Nervous and Mental Disease, 1975, 161, 255–264.Google Scholar
  143. Vidal, G., & Vidal, B. Imipramine et obsessions. Encephale, 1963, 52, 167–180.PubMedGoogle Scholar
  144. Visitini, F. Terapia degli stati depressivi con Tofranil. Giornale Psychiatrico Neuropatologico, 1959, 30, 3–8.Google Scholar
  145. Waxman, D. A general practice investigation on the use of clomipramine in obsessional and phobic disorders. Journal of International Medical Research, 1973, 1, 417–420.Google Scholar
  146. Waxman, D. An investigation into the use of anafranil in phobic and obsessional disorders. Scottish Medical Journal, 1975, 20, 61–66.PubMedGoogle Scholar
  147. Weissman, M., & Bothwell, S. Assessment of social adjustment by patient self-report. Archives of General Psychiatry, 1976, 33, 111–115.Google Scholar
  148. Woodruff, R., & Pitts, F. M. Monozygotic twins with obsessional illness. American Journal of Psychiatry, 1964, 120, 1075–1080.PubMedGoogle Scholar
  149. Wyndowe, J., Solyom, L., & Ananth, J. Anafranil in obsessive compulsive neurosis. Current Therapeutic Research, 1975, 18, 611–617.PubMedGoogle Scholar
  150. Yaryura-Tobias, J. A., & Bhagawan, H. N. L-tryptophan in obsessivecompulsive disorders. American Journal of Psychiatry, 1977, 134, 1298–1299.PubMedGoogle Scholar
  151. Yaryura-Tobias, J. A., Neziroglu, F., & Bergman, L. Clomipramine for obsessive compulsive neurosis: An organic approach. Current Therapeutic Research, 1976, 20, 541–547.Google Scholar
  152. Youdim, M. B. H. Multiple forms of mitrochondrial monoamine oxidase. British Medical Bulletin, 1973, 29, 120–122.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Jambur Ananth
    • 1
  1. 1.Psychopharmacology Harbor, UCLA Medical CenterUniversity of California at Los AngelesTorranceUSA

Personalised recommendations